ProKidney Corp. shared its Q3 2026 results, showing a loss and updates on its clinical trials.

Nov 12, 2026, 4:34 PM ETResultsRead the original at SEC EDGAR

Good for PROK

ProKidney's main Phase 3 study remains on schedule, and faster enrollment is expected to bring the confirmatory group above 500 patients. Cash fell and the quarterly loss grew, but the company says its funds support operations into mid-2027, near its expected first results.

PROK · ProKidney Corp.

AI read · Good for PROK

The AI's read

Steady enrollment keeps the main study moving toward its first major result. New kidney-disease data add support for rilparencel, but they do not prove it works. The quarterly loss grew to about $52 million from $36 million a year earlier, and cash fell to $142 million from $182 million. The company says its cash should support operations into mid-2027, close to the planned first results.

Get alerts for PROK

Follow ProKidney Corp. (PROK) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PROK

Free on the App Store and Google Play, or on the web.